

LIBROS

Rayssiguier Y, Mazur A, Durlach J, eds. *Advances in magnesium research: Nutrition & health*. Eastleigh: John Libbey, 2001.

NÚMEROS MONOGRÁFICOS

Gasser JA. Bone anabolic agents. *J Musculoskel Neuron Interact* 2001; 2: 1-84.

NUESTROS AUTORES

Hawkins Carranza F. La situación actual de la utilización de la calcitonina en la osteopenia/osteoporosis. *Rev Clin Esp* 2001; 207: 463-5.

Fiter J, Nolla JM, Gómez-Vaquero C, et al. A comparative study of computed digital absorptiometry and conventional dual-energy X-ray absorptiometry in postmenopausal women. *Osteoporosis Int* 2001; 12: 565-9.

López-Ibarra PJ, Campos MM, Escobar-Jiménez F, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. *Endocrine Pract* 2001; 7: 127-31.

Nieto E, Useche R, Natale A. Mortality after hip fracture in patients > 60 years old. *Bone* 2001; 29: 303.

Vega E, Mautalen C, Merlo C, Poitevin L. Bone mineral density in men who have sustained a hip fracture is higher than in women. *Bone* 2001; 29: 302-2.

Marco-Mingot M, San Millán JL, Wuyts W, et al. Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. *Clin Genet* 2001; 60: 86-8.

Ferreira A, Ghazali A, Galvao J, et al. Effect of type of dialysis membrane on bone in haemodialysis patients. *Nephrol Dial Transplant* 2001; 16: 1230-8.

Se ruega a los autores enviar una copia del trabajo para incluir su cita en esta Sección.

REVISIONES

Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship and accountability. *N Engl J Med* 2001; 345: 825-7.

Sipila S, Taaffe DR, Cheng S, et al. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. *Clin Sci* 2001; 101: 147-57.

Pierard GE, Pierard-Franchimont C, Vanderplaetsen S, et al. Relationship between bone mass density and tensile strength of the skin in women. *Eur J Clin Invest* 2001; 31: 731-5.

Wronski TJ. Skeletal effects of systemic treatment with basic fibroblast growth factor. *J Musculoskel Neuron Interact* 2001; 2: 9-14.

Hartke JR, Lundy MW. Bone anabolic therapy with selective prostaglandins analogs. *J Musculoskel Neuron Interact* 2001; 2: 25-32.

Hinnie J, Bell E, McKillop E, et al. The prevalence of familial hypocalciuric hypercalcemia. *Calcif Tissue Int* 2001; 68: 216-28.

Currey JD. Bone strength: what are we trying to measure? *Calcif Tissue Int* 2001; 68: 205-10.

Dawson-Hughes B. Bone loss accompanying medical therapies. *N Engl J Med* 2001; 345: 989-91.

Stavrou S, Kleinberg DL. Diagnosis and management of growth hormone deficiency in adults. *Endocrinol Metab Clin North Am* 2001; 30: 545-63.

Perron AD, Brady WJ, Keats TA. Principles of street fracture management. The whys and hows of an increasingly common injury. *Postgrad Med* 2001; 110: 115-8.

Southerland JC, Valentine JF. Osteopenia and osteoporosis in gastrointestinal diseases: diagnosis and treatment. *Curr Gastroenterol Rep* 2001; 3: 399-407.

Takahashi M. The GDNF/RET signaling pathway and human diseases. *Cytokine Growth Factor Rev* 2001; 12: 361-73.

Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. *Curr Med Chem* 2001; 8: 1679-97.

McCauley LK. Transgenic mouse models of metabolic bone disease. *Curr Opin Rheumatol* 2001; 13: 316-25.

Sikavitsas VI, Temenoff JS, Mikos AG. Biomaterials and bone mechanotransduction. *Biomaterials* 2001; 22: 2581-93.

Drueke TB. Genetics aspects of secondary hyperparathyroidism in uremia. *Am J Kidney Dis* 38: S143-6.

Mundy G. Anabolic agents for osteoporosis. *Bone* 2001; 29: 295-6.

Canalis E. New treatments in osteoporosis. *Bone* 2001; 29: 296.

OTROS ARTÍCULOS DE INTERÉS

Hall WD, Pettinger M, Oberman A, et al. Risk factors for kidney stones in older women in the Southern United States. *Am J Med Sci* 2001; 322: 12-8.

Hogan DB, MacDonald FA, Betts J, et al. A randomized controlled trial of a community-based consultation service to prevent falls. *CMAJ* 2001; 165: 537-43.

Hsieh C, Novielli KD, Diamond JJ, Cheruva D. Health beliefs and attitudes toward the prevention of osteoporosis in older women. *Menopause* 2001; 8: 372-6.

Juby AG, Davis P. A prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjects. *Osteoporosis Int* 2001; 12: 617-23.

Voort DJM, Geusens PP, Dinant GJ. Risk factors for the osteoporosis related to their outcome: Fractures. *Osteoporosis Int* 2001; 12: 630-8.

Chrischilles EA, Dasbach EJ, Rubinstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and

- costs: The fracture intervention trial. *Osteoporosis Int* 2001; 12: 654-60.
- Lunt M, Masaryk P, Scheidt C, et al. The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: The EVOS Study. *Osteoporosis Int* 2001; 12: 688-98.
- Damilakis J, Perisinakis K, Gouurtsoyiannis N. Imaging ultrasonometry of the calcaneus: optimum T-score thresholds for the identification of osteoporotic subjects. *Calcif Tissue Int* 2001; 68: 219-24.
- Tominaga Y, Uchida K, Haba T, et al. More than 1.000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. *Am J Kidney Dis* 2001; 38: 168-71.
- Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. *Obstet Gynecol* 2001; 98: 576-82.
- Nuti R, Martini G, Valenti R, et al. Prevalence of undiagnosed coeliac syndrome in osteoporotic women. *J Intern Med* 2001; 250: 361-16.
- Israel E, Banerjee TR, Fitzmaurice GM. Effects of inhaled glucocorticoids on bone density in premenopausal women. *N Engl J Med*. 2001; 345: 941-7.
- Chou FF, Chen JB, Lee CH, et al. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. *Arch Surg* 2001; 136: 1064-8.
- Schimmer AD, Mah K, Bordeleau L, et al. Decreased bone mineral density is common after autologous blood or marrow transplantation. *Bone Marrow Transplant* 2001; 28: 387-91.
- Curry LC, Hogstel MO. Risk status related to knowledge of osteoporosis in older women. *J Women Aging* 2001; 13: 71-83.
- Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. *Blood* 2001; 98: 2269-71.
- Griffith K, Pearson D, Parker C, et al. The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease. *Nucl Med Commun*. 2001; 22: 1069-75.
- Valmadrid C, Voorhees C, Litt B. Practice Patterns of Neurologist Regarding Bone and Mineral Effects of Antiepileptic Drug Therapy. *Arch Neurol* 2001; 58: 1369-74.
- Goemaere S, Van Pottelberg I, Zmierzak H, et al. Inverse association between bone turnover rate and bone mineral density in community-dwelling men > 70 years of age: no major role of sex steroid status. *Bone* 2001; 29: 286-91.
- Bord S, Beavan S, Ireland D. Mechanism by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors. *Bone* 2001; 29 (3): 216-22.

PREMIOS AL MEJOR TRABAJO EN REEMO 2001

EDICIONES DOYMA, S.A.

CONVOCA

LOS PREMIOS AL MEJOR TRABAJO ORIGINAL Y AL MEJOR TRABAJO CLÍNICO
PUBLICADOS EN LA REVISTA ESPAÑOLA DE ENFERMEDADES METABÓLICAS ÓSEAS
DURANTE EL AÑO 2001

1. Concurren a él todos los trabajos originales y clínicos publicados en la REVISTA ESPAÑOLA DE ENFERMEDADES METABÓLICAS ÓSEAS, durante el año 2001.
2. El Consejo Editorial realizará para cada grupo una selección de los tres mejores trabajos.
3. El Comité Editorial posteriormente otorgará un premio de 100.000 ptas, acompañado de un diploma, al mejor trabajo de cada grupo. El premio será entregado al primer firmante del trabajo.
4. Las decisiones de los Jurados responderán a criterios de independencia y de objetividad.
5. El resultado será hecho público en la VII Reunión SEIOMM de 2002.